Interested in speaking? Apply Here!

Agenda

We are currently shaping the agenda for MASS East 2018 in order to identify current trends, areas of interest and common challenges so we can be sure the topics selected for sessions reflect the industry’s needs and wants. If you’d like to be involved in this process and/or get involved as a speaker, panelist or roundtable moderator, please contact Mercy Lister at mlister@exlevents.com and Zohaib Sheikh at zsheikh@exlevents.com.

MEDICAL AFFAIRS EXECUTIVE STRATEGY MSL BEST PRACTICES RESEARCH COLLABORATION AND INVESTIGATOR-INITIATED TRIALS
  • Develop a holistic and patient-centered evidence generation process to achieve optimal reimbursement
  • Transform your medical affairs team into a strategic partner by providing market-based input into portfolio management and field insights
  • Explore the role of social media and digital health in medical affairs
  • Navigate the regulatory landscape of off-label communication
  • Ensure the impact and value of medical initiatives to internal and external stakeholders is well understood
  • Define meaningful KPIs for measuring the quality and impact of thought leader engagement
  • Create a process to collect, manage and communicate meaningful field insights back to the organization
  • Learn how to develop field medical excellence centers and operational models
  • Ensure effective coaching and training to build technical and leadership skills for maximum performance and long term succession planning
  • Maximize the value of field medical affairs for clinical trial success
  • Successfully Integrate a Quality Component into Investigator-Initiated Trials
  • Prevent Non-Compliance and Steps to Take When It Occurs in Investigator-Initiated Trials
  • Develop an Efficient Process for Fair-Market Value Analysis of Budgets for Investigator-sponsored Trials
  • Field Medical Affairs in IITs: Leveraging Risk- Tolerance Models to Ensure Compliant and Strategic KOL Engagements
  • Examine How To Optimize The Approach To The ICH E6 (GCP) Addendum In Investigator-Initiated Trials

Request More Information

More Info
live chat software